Category: Uncategorized

THERE ARE DIFFERENT RULES FOR DIFFERENT SPACES IN ENTREPRENEURING and when the rules become generalized they become less true or even useless. Social media is different from Biopharma. In Biopharma there is no "launch early" and most "disruptive" plays have been made decades ago. Make sure you don't get confused by great advice from an unrelated sector. http://lnkd.in/pkcuyK View in LinkedIn

CHINA'S INTEREST IN BIOTECH DRUGS IS SPURRING INVESTMENTS. Capable of implementing very long-term and well-funded initiatives, China is becoming an influential player in world investment markets. The JPM breakout session a couple of years ago featured Chinese Pharma companies talking about brand drugs. This was a significant sea change, because it meant that they would enforce patent protection. Watch this space. http://lnkd.in/Swa-RQ View in LinkedIn

"CAN YOU MAKE GUMBOOTS FOR FROGS OUT OF THIS?" my old chemistry professor used to say. This memorably zany question stuck front and central un my brain thereafter. It was a repurposing question before we were using the word repurposing. Taffy's great article highlights the benefits of repurposing beyond pharmaceuticals. http://lnkd.in/umerTY View in LinkedIn

THE BEIJING GENOMICS INSTITUTE, with a whopping 4,000 staff and a massive 1.58 B USD funding, is a phenomenal undertaking. Symbolic of the future power of DNA sequencing and its applications, it gives a boost to biotech worldwide. The time for harnessing international collaborations with such giants is now. http://lnkd.in/WK9r-g View in LinkedIn

0 View in LinkedIn

WESTERN PHARMA's R&D MODEL is clearly broken, so just ranking highly for throwing capital at a research organization is not impressive. Better to see that capital divided into numerous outsourced financings with small innovative companies, who are infinitely mire productive and imaginative. http://m.timesofindia.com/business/india-business/Indian-companies-top-global-charts-for-investment-in-RD/articleshow/18099909.cms View in LinkedIn

0 View in LinkedIn

PATIENT OUTCOMES are becoming an important metric for new drugs, and long overdue. Gatekeeping of a successful medicine has shifted in recent years from the FDA to payers, and pharmacoeconomics, as the UK's NICE committee has recently demonstrated in exclusion decisions for expensive drugs. http://lnkd.in/dejJgi View in LinkedIn

0 View in LinkedIn

MANAGEMENT, MANAGEMENT, MANAGEMENT, is a key to startups, as true as location is in real estate transactions. One trait I have observed in several talented Founder-CEOs is a curious loyalty and hesitancy to fire a bad apple even when it is clearly the case. In all instances, after-the-fact relief was experienced, along with the realization it was very long overdue. Act decisively, be fair and consistent, and this includes acknowledging YOU made the bad hire. People will understand. http://lnkd.in/tGUwYJ View in LinkedIn